CARD10 and non-small cell lung carcinoma: To better claim the correlation of CARMA3 with lung cancer progression, we evaluated the relationship between the expression of CARMA3 and overall survival of N0 stage NSCLC patients(38 CAMRA3+ and 16 CAMRA3 - ).